Lista de obras -

'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'.

artículo científico publicado en 2007

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

artículo científico publicado en 2019

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models

artículo científico publicado en 2017

A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE

Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer

Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?

artículo científico publicado en 2014

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

scientific article published on 01 December 2018

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT ⬇️

scholarly article by Sarah Brown et al published June 2018 in Health Technology Assessment

An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer

artículo científico publicado en 2011

Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al

artículo científico publicado en 2007

Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma ⬇️

artículo científico publicado en 2018

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.

artículo científico publicado en 2015

Building a Decision Tree Cost Effectiveness Model

article

Building a Markov Cost Effectiveness Model in Excel

article

Cancer Drugs Fund 2.0: A Missed Opportunity?

artículo científico publicado en 2016

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

artículo científico publicado en 2016

Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT

scientific article published on 01 September 2019

Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilities

artículo científico publicado en 2013

Continuing the multiple sclerosis risk sharing scheme is unjustified

artículo científico publicado en 2010

Correlated Parameters and the Cholesky Decomposition

Cost Effectiveness Modelling for Health Technology Assessment

article

Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus

artículo científico publicado en 2016

Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists

artículo científico publicado en 2010

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

artículo científico publicado en 2009

Determinants of Change in the Cost-effectiveness Threshold

artículo científico publicado en 2016

Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.

artículo científico publicado en 2016

Economic Evaluation, Cost Effectiveness Analysis and Health Care Resource Allocation

article

Economic considerations in the provision of treatments for rare diseases.

scientific article published on January 2010

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer ⬇️

artículo científico publicado en 2011

Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions

artículo científico publicado en 2013

Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation

artículo científico publicado en 2012

Erratum to ‘Health state values for the health utilities index mark 2 descriptive system: results from a UK valuation survey’Health Economics 2005;14(3): 231–244

article

Expected net present value of sample information: from burden to investment ⬇️

artículo científico publicado en 2012

Finding the Evidence for Decision Analytic Cost Effectiveness Models

article

Hard choices: Reflections from the tomb of the unknown patient

artículo científico publicado en 2019

Health economics in drug development: efficient research to inform healthcare funding decisions

artículo científico publicado en 2010

Health state values for the HUI 2 descriptive system: results from a UK survey

article

Health technology funding decision-making processes around the world: the same, yet different

artículo científico publicado en 2011

Incorporation of uncertainty in health economic modelling studies

article

Introduction to Markov Cost Effectiveness Models

Investing in Health Care, Research and the Value of Information

article

Is it time to revisit orphan drug policies? ⬇️

artículo científico publicado el 22 de septiembre de 2010

Low-value approvals and high prices might incentivize ineffective drug development

scientific article published on 01 July 2018

Making a Markov Model Probabilistic

article

Marketing of unproven stem cell-based interventions: A call to action

artículo científico publicado en 2017

Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and Mushlin

artículo científico publicado en 2014

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT ⬇️

article

Modeling HUI 2 health state preference data using a nonparametric Bayesian method

artículo científico publicado en 2008

Multi-attribute utility function or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system.

artículo científico publicado en 2007

Navigating time and uncertainty in health technology appraisal: would a map help?

artículo científico publicado en 2013

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

artículo científico publicado en 2016

Objectivity and equity: clarity required. A response to Hill and Olson

artículo científico publicado en 2014

One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit

scientific article published on 01 February 2020

Orphan drugs and the NHS: should we value rarity?

artículo científico publicado en 2005

Outputs from Probabilistic Sensitivity Analysis

Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation ⬇️

artículo científico publicado en 2017

Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier

scientific article published on 23 November 2020

Probability Distributions for Cost and Utility Parameters

article published in 2015

Probability Distributions for Effectiveness Parameters

Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate

artículo científico publicado en 2013

Response to Shmueli

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe ⬇️

artículo científico publicado el 30 de agosto de 2011

Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence

scientific article published on 01 January 2007

Self-Harm Intervention: Family Therapy (SHIFT), a study protocol for a randomised controlled trial of family therapy versus treatment as usual for young people seen after a second or subsequent episode of self-harm ⬇️

artículo científico publicado en 2015

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines

artículo científico publicado en 2016

Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?

artículo científico publicado en 2014

Show drugs work before selling them.

artículo científico publicado en 2017

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

artículo científico publicado en 2020

Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment

artículo científico publicado en 2020

Some inconsistencies in NICE's consideration of social values

artículo científico publicado en 2014

Stem cells and beta cell replacement therapy: a prospective health technology assessment study.

artículo científico publicado en 2018

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug ⬇️

artículo científico publicado en 2014

The Incremental Cost Effectiveness of Withdrawing Pulmonary Artery Catheters from Routine Use in Critical Care

scientific article published on 01 January 2005

The NICE cost-effectiveness threshold: what it is and what that means

artículo científico publicado en 2008

The STAR trial: can quality of life benefit offset any survival detriment?

artículo científico publicado en 2011

The authors’ reply

The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study.

artículo científico publicado en 2015

To fund or not to fund: development of a decision-making framework for the coverage of new health technologies

artículo científico publicado el 1 de septiembre de 2011

Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses

Understanding Harris' understanding of CEA: is cost effective resource allocation undone? ⬇️

artículo científico publicado en 2013

Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product

artículo científico publicado en 2016

Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence

artículo científico publicado en 2011

Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis

artículo científico publicado en 2015

Use of visual analog scales in economic evaluation

scientific article published on 01 June 2003

Using rank data to estimate health state utility models ⬇️

artículo científico publicado en 2006

Value based pricing for NHS drugs: an opportunity not to be missed?

artículo científico publicado en 2008

Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial ⬇️

artículo científico publicado en 2017

Value of Information in Health Technology Regulation and Reimbursement

article

Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework

artículo científico publicado en 2015

Value-engineered translation for regenerative medicine: meeting the needs of health systems.

artículo científico publicado en 2013

Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected ⬇️

artículo científico publicado en 2009

What Evidence Is There for the Reimbursement of Personalised Medicine? ⬇️

artículo científico publicado el 1 de marzo de 2013

Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement

artículo científico publicado en 2008

Lista de obras de

'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models

A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE

Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer

Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice?

Addendum: Low-value approvals and high prices might incentivize ineffective drug development

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT ⬇️

An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer

Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al

Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma ⬇️

Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.

Building a Decision Tree Cost Effectiveness Model

Building a Markov Cost Effectiveness Model in Excel

Cancer Drugs Fund 2.0: A Missed Opportunity?

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT

Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilities

Continuing the multiple sclerosis risk sharing scheme is unjustified

Correlated Parameters and the Cholesky Decomposition

Cost Effectiveness Modelling for Health Technology Assessment

Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus

Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population

Determinants of Change in the Cost-effectiveness Threshold

Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.

Economic Evaluation, Cost Effectiveness Analysis and Health Care Resource Allocation

Economic considerations in the provision of treatments for rare diseases.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer ⬇️

Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions

Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation

Erratum to ‘Health state values for the health utilities index mark 2 descriptive system: results from a UK valuation survey’Health Economics 2005;14(3): 231–244

Expected net present value of sample information: from burden to investment ⬇️

Finding the Evidence for Decision Analytic Cost Effectiveness Models

Hard choices: Reflections from the tomb of the unknown patient

Health economics in drug development: efficient research to inform healthcare funding decisions

Health state values for the HUI 2 descriptive system: results from a UK survey

Health technology funding decision-making processes around the world: the same, yet different

Incorporation of uncertainty in health economic modelling studies

Introduction to Markov Cost Effectiveness Models

Investing in Health Care, Research and the Value of Information

Is it time to revisit orphan drug policies? ⬇️

Low-value approvals and high prices might incentivize ineffective drug development

Making a Markov Model Probabilistic

Marketing of unproven stem cell-based interventions: A call to action

Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and Mushlin

Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT ⬇️

Modeling HUI 2 health state preference data using a nonparametric Bayesian method

Multi-attribute utility function or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system.

Navigating time and uncertainty in health technology appraisal: would a map help?

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Objectivity and equity: clarity required. A response to Hill and Olson

One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit

Orphan drugs and the NHS: should we value rarity?

Outputs from Probabilistic Sensitivity Analysis

Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation ⬇️

Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier

Probability Distributions for Cost and Utility Parameters

Probability Distributions for Effectiveness Parameters

Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate

Response to Shmueli

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe ⬇️

Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence

Self-Harm Intervention: Family Therapy (SHIFT), a study protocol for a randomised controlled trial of family therapy versus treatment as usual for young people seen after a second or subsequent episode of self-harm ⬇️

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines

Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?

Show drugs work before selling them.

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment

Some inconsistencies in NICE's consideration of social values

Stem cells and beta cell replacement therapy: a prospective health technology assessment study.

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug ⬇️

The Incremental Cost Effectiveness of Withdrawing Pulmonary Artery Catheters from Routine Use in Critical Care

The NICE cost-effectiveness threshold: what it is and what that means

The STAR trial: can quality of life benefit offset any survival detriment?

The authors’ reply

The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study.

To fund or not to fund: development of a decision-making framework for the coverage of new health technologies

Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses